Target-specific CRISPR mutant
AssigneeToolgen Incorporated
InventorsYoung-Hoon Kim, Min Hee Jung, Joonsun Lee, Eunji Shin, Kang In Lee, Seokjoong Kim, Jeongjoon Lee
Life of this patent
Estimating the term…
Abstract
The present invention relates to an artificially engineered CRISPR/Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR/Cas9 system including the same enzyme in genome and/or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.
Claims6
A SpCas9 (Streptococcus pyogenes Cas9) variant comprising all of SEQ ID NO:
- 1 except for (i) a serine at the position corresponding to position 539 of the polypeptide of SEQ ID NO:
- 1;
- (ii) an isoleucine at the position corresponding to position 763 of the polypeptide of SEQ ID NO:
- 1;
- and (iii) an asparagine at the position corresponding to position 890 of the polypeptide of SEQ ID NO:
- 1, and wherein the SpCas9 variant has an endonuclease activity.
A composition for gene modification comprising a Cas9 and a guide RNA, wherein the Cas9 is a Streptococcus pyogenes Cas9 (SpCas9) variant comprising all of SEQ ID NO:
- 1 except for (i) a serine at the position corresponding to position 539 of the polypeptide of SEQ ID NO:
- 1;
- (ii) an isoleucine at the position corresponding to position 763 of the polypeptide of SEQ ID NO:
- 1;
- and (iii) an asparagine at the position corresponding to position 890 of the polypeptide of SEQ ID NO:
- 1, and wherein the guide RNA is complementary to a target gene.
Dependencies are inferred from the claim text.